We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking CTCs and Neutrophils Could Prevent Cancer Metastasis

By LabMedica International staff writers
Posted on 21 Feb 2019
A mechanism has been proposed that explains why the association of circulating tumor cells (CTCs) and immune neutrophils enhances the ability of the cancer cells to form metastases.

CTCs are precursors of metastasis in several types of cancer and are occasionally found within the bloodstream in association with non-malignant cells such as white blood cells (WBCs). More...
The identity and function of these CTC-associated WBCs, as well as the molecular features that define the interaction between WBCs and CTCs, has been poorly defined.

To help clarify the nature of this interaction, investigators at the University of Basel (Switzerland) isolated and characterized individual CTC-associated WBCs, as well as corresponding cancer cells within each CTC–WBC cluster, from patients with breast cancer and from mouse models. They used single-cell RNA sequencing to show that in the majority of these cases, CTCs were associated with neutrophils.

The investigators reported in the February 6, 2019, online edition of the journal Nature that by comparing the transcriptome profiles of CTCs associated with neutrophils against those of CTCs alone, they detected a number of differentially expressed genes that outlined cell cycle progression, leading to more efficient metastasis formation. Furthermore, they identified cell–cell junction and cytokine–receptor pairs that defined CTC–neutrophil clusters, representing key vulnerabilities of the metastatic process.

The investigators concluded that the association between neutrophils and CTCs drove cell cycle progression within the bloodstream and expanded the metastatic potential of CTCs, which provides a rationale for targeting this interaction in treatment of breast cancer.

"Surprising is that the patient's own neutrophils act by protecting CTCs in circulation, allowing CTCs to more efficiently seed metastasis", said senior author Dr. Nicola Aceto, assistant professor of oncology at the University of Basel. "We undertook a number of experiments to fully characterize CTC-neutrophil clusters from patients and mouse models, aiming to find strategies to suppress their ability to form metastasis. Indeed, the presence of CTC-neutrophil clusters in the bloodstream also correlates with a poor prognosis of breast cancer patients."

Related Links:
University of Basel


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.